Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
None USD 0.00(0%)
Last update at 2024-03-05T21:00:51.180802Z
Market Cap
0.00M

Momentum Score

…

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida. On October 22, 2023, Akumin Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.14
Low
0.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.38
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
1215.19M
ROCE
2.47%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -143.18M -65.20M -23.42M 11.44M
Minority interest -5.17M -8.48M -2.73M -2.20M
Net income -156.76M -43.29M -20.40M 6.45M
Selling general administrative 3.24M 2.79M 2.08M 3.55M
Gross profit 141.25M 61.34M 53.48M 77.56M
Reconciled depreciation 98.20M 44.90M 20.46M 28.27M
Operating income 39.43M 13.82M 30.94M 45.74M
Interest expense 118.01M 62.58M 32.78M 28.94M
Tax provision 8.41M -30.39M -5.75M 2.79M
Net interest income -118.01M -62.58M -32.78M -28.94M
Total revenue 749.63M 421.08M 251.28M 247.44M
Total operating expenses 710.20M 407.26M 220.35M 201.70M
Cost of revenue 608.38M 359.74M 197.80M 169.87M
Total other income expense net -64.59M -16.45M -21.57M -5.36M
Net income from continuing ops -151.59M -34.81M -17.67M 8.65M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1765.12M 1918.83M 718.68M 663.38M
Intangible assets 392.10M 414.15M 6.75M 9.39M
Other current assets 10.35M 7.03M - -
Total liab 1623.82M 1597.68M 578.95M 521.79M
Total stockholder equity -48.20M 105.19M 134.21M 138.69M
Other current liab - - 4.69M 7.53M
Capital stock 0.90M 228.59M 160.97M 152.00M
Retained earnings -280.19M -123.42M -26.76M -20.19M
Good will 769.11M 840.35M 360.60M 342.22M
Cash 59.42M 48.42M 44.40M 23.39M
Total current liabilities 168.52M 164.18M 51.94M 48.44M
Net debt 1215.19M 1163.97M 345.59M 317.68M
Short long term debt 19.96M 14.79M 0.41M 3.71M
Total current assets 191.94M 185.16M 139.47M 110.18M
Net receivables 114.17M 121.53M 91.13M 82.87M
Long term debt 1254.65M 1197.60M 389.58M 337.36M
Accounts payable 36.62M 34.33M 20.40M 21.71M
Non currrent assets other 23.93M 25.48M - -
Non current assets total 1573.17M 1733.66M 579.22M 553.20M
Capital lease obligations 205.00M 227.58M 147.87M 137.10M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -38.70M -779.17M -17.08M -231.11M
Total cash from financing activities -15.66M 766.14M 11.40M 215.31M
Net income -156.76M -43.29M -20.40M 6.45M
Change in cash 11.01M 4.02M 21.01M 4.06M
Begin period cash flow 48.42M 44.40M 23.39M 19.33M
End period cash flow 59.42M 48.42M 44.40M 23.39M
Total cash from operating activities 65.37M 17.05M 26.69M 19.86M
Issuance of capital stock 0.07M 10.51M 0.00M 1.31M
Depreciation 98.20M 44.90M 20.46M 28.27M
Change to account receivables 14.33M 12.31M -8.26M -25.24M
Capital expenditures 44.76M 17.87M 13.42M 12.45M
Change in working capital 18.12M 20.62M 3.59M -27.53M
Stock based compensation 3.24M 2.79M 2.08M 3.55M
Other non cash items 42.18M 14.09M 5.48M 1.93M
Free cash flow 20.61M -0.82M 13.27M 7.41M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
TMO
Thermo Fisher Scientific Inc
-17.51
2.54%
671.24 34.71 23.87 4.62 4.43
DHR
Danaher Corporation
-0.25
0.11%
220.36 29.09 28.01 5.67 3.20
WUXIF
WuXi AppTec Co. Ltd
-
-%
23.77 22.29 17.95 1.53 5.98
WUXAY
WuXi AppTec Co. Ltd
-0.92
3.87%
22.85 23.28 18.73 1.51 6.24

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…